Financings in Brief: Genzyme
This article was originally published in The Gray Sheet
Executive Summary
Genzyme: Withdraws its previously announced stock offer to buy all assets of Genzyme Development Partners, L.P., also known as the Surgical Aids Partnership. The Partnership is developing surgical products based on hyaluronic acid, including Seprafilm bioresorbable membrane, Sepracoat coating solution, Sepragel bioresorbable gel, and Hal-S synovial fluid replacement. Instead of the acquisition offer, which was valued at about $93 mil. when it was made in February ("The Gray Sheet" Feb. 12, p. 16), Genzyme says it will continue to pursue its "established contractual relationship" with the partnership. Under the existing deal, Genzyme has the option to purchase all outstanding partnership interests for $25.8 mil. "and future royalty payments on surgical product sales for 10 years following the date of purchase."
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.